The demand for Lipid-Lowering Agents in Jordan has been increasing steadily in recent years.
Customer preferences: There is a growing awareness among Jordanians about the importance of maintaining a healthy lifestyle, which includes a balanced diet and regular exercise. As a result, many people are seeking medical assistance to lower their cholesterol levels and reduce the risk of heart disease. Additionally, the aging population in Jordan is also contributing to the rising demand for Lipid-Lowering Agents.
Trends in the market: The Lipid-Lowering Agents market in Jordan is dominated by statins, which are the most commonly prescribed drugs for lowering cholesterol levels. However, there has been a shift towards the use of alternative medications such as PCSK9 inhibitors and bile acid sequestrants, which are becoming more widely available in the market. This trend is expected to continue as more patients are seeking personalized treatment options.
Local special circumstances: One of the unique challenges in the Jordanian market is the high prevalence of diabetes, which is a risk factor for heart disease. As a result, many patients require combination therapy with Lipid-Lowering Agents and antidiabetic medications. Additionally, the cost of medication is a major concern for many Jordanians, and there is a growing trend towards generic drugs as a more affordable option.
Underlying macroeconomic factors: The healthcare sector in Jordan is heavily reliant on government funding, which has been under strain due to the influx of refugees from neighboring countries. This has led to a shortage of resources and increased pressure on the healthcare system. Despite these challenges, the Jordanian government has implemented policies to promote the use of generic drugs and increase access to healthcare services, which is expected to drive growth in the Lipid-Lowering Agents market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
